THE DEVELOPER
Rethiamine by Panacea Bio Chem
Rethiamine™ was conceived by Bogdan Dicoias within Panacea Bio Chem ↗ as a pharmaceutical formulation response to an emerging problem: increasingly powerful weight-reduction technologies may require equally thoughtful nutritional and formulation support.
Panacea Bio Chem is visibly responsible for the concept: the formulation architecture, the dual-layer Peptourbillon™, the Lyoprester SS™ integration and the P-EARLs™ reconstitution logic are Panacea development work, and the three research identities — Rethiamine™, Reta-B1™ and RetaBone™ — are Panacea names for one formulation.
Where Rethiamine sits in the estate
One formulation concept, expressed through three research identities, built on Panacea platform technologies.
- Panacea Bio Chem ↗
- Rethiamine™ proprietary formulation
- Dual-layer Peptourbillon™ ↗
- Frozen retatrutide lower layer
- Supercooled thiamine upper layer
- Lyoprester SS™ protected single-shot platform ↗
- P-EARLs™ 0.5 mL conflict-reconciling reconstitution
- Reta-B1™ technical research identity ↗
- RetaBone™ metabolic and body-composition research identity ↗
The connected technologies
Bogdan Dicoias — Panacea Bio Chem Ltd
THE FORMULATION ARCHITECT
Developed within the Panacea Bio Chem research universe
“A medicine should not be designed only around its primary pharmacology. It should also be designed around the physiological environment that pharmacology creates.”
Provenance and responsibility
Formulation concept and platform integration by Bogdan Dicoias and Panacea Bio Chem. Retatrutide is an investigational molecule developed by Eli Lilly and Company; Panacea Bio Chem has no affiliation with the developer of retatrutide, and Rethiamine is an independent formulation research programme built around the published scientific profile of the molecule. Company provenance: Panacea Bio Chem proprietary formulation research ↗.